Les activités du CHUV
Centre des tumeurs thoraciques
Accueil > Recherche > Publications > Publications 2013

Publications de l'année 2013

Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.

Gautschi O, Peters S, Zoete V, Aebersold-Keller F, Strobel K, Schwizer B, Hirschmann A, Michielin O, Diebold J.

Lung Cancer. 2013 Nov;82(2):365-7. doi: 10.1016/j.lungcan.2013.08.012. Epub 2013 Aug 19. PMID: 24035431

Practical tips and tricks with recently approved molecular targeted agents in non-small-cell lung cancer.

Zimmermann S, Peters S.

EJC Suppl. 2013 Sep;11(2):307-9. doi: 10.1016/j.ejcsup.2013.07.058. Review. No abstract available.

PMID: 26217155

Treatment and detection of ALK-rearranged NSCLC.

Peters S, Taron M, Bubendorf L, Blackhall F, Stahel R.

Lung Cancer. 2013 Aug;81(2):145-54. doi: 10.1016/j.lungcan.2013.03.017. Epub 2013 Jun 12. Review.

PMID: 23769207

Impact of induction therapy on airway complications after sleeve lobectomy for lung cancer.

Gonzalez M, Litzistorf Y, Krueger T, Popeskou SG, Matzinger O, Ris HB, Gronchi F, Lovis A, Peters S.

Ann Thorac Surg. 2013 Jul;96(1):247-52. doi: 10.1016/j.athoracsur.2013.04.009. Epub 2013 May 16.

PMID: 23684158

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.

Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, Moro-Sibilot D, Dansin E, Chouaid C, Wislez M, Diebold J, Felip E, Rouquette I, Milia JD, Gautschi O.

J Clin Oncol. 2013 Jun 1;31(16):1997-2003. doi: 10.1200/JCO.2012.45.6095. Epub 2013 Apr 22. PMID:23610105

A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable?

Demierre N, Zoete V, Michielin O, Stauffer E, Zimmermann DR, Betticher DC, Peters S.

Lung Cancer. 2013 Apr;80(1):81-4. doi: 10.1016/j.lungcan.2012.11.013. Epub 2013 Feb 4. PMID: 23380224

Targeting receptor activator of nuclear factor-kappa B as a new therapy for bone metastasis in non-small cell lung cancer.

Peters S, Meylan E.

Curr Opin Oncol. 2013 Mar;25(2):137-44. doi: 10.1097/CCO.0b013e32835d720b. Review. PMID: 23283210

VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528.

Gautschi O, Dingemans AM, Crowe S, Peters S, Roder H, Grigorieva J, Roder J, Zappa F, Pless M, Brutsche M, Baty F, Bubendorf L, Hsu Schmitz SF, Na KJ, Carbone D, Stahel R, Smit E.

Lung Cancer. 2013 Jan;79(1):59-64. doi: 10.1016/j.lungcan.2012.10.006. Epub 2012 Nov 1. PMID: 23122759

Diagnosis and management of chronic obstructive pulmonary disease: the Swiss guidelines. Official guidelines of the Swiss Respiratory Society.

Russi EW, Karrer W, Brutsche M, Eich C, Fitting JW, Frey M, Geiser T, Kuhn M, Nicod L, Quadri F, Rochat T, Steurer-Stey C, Stolz D; Swiss Respiratory Society.

Respiration. 2013;85(2):160-74. doi: 10.1159/000346025. Epub 2013 Feb 11. Review. PMID: 23406723

The intrathoracic vacuum-assisted closure device in case of post-pneumonectomy empyema.

Krueger T, Perentes JY, Ris HB, Gonzalez M.

Eur J Cardiothorac Surg. 2013 May;43(5):1077. doi: 10.1093/ejcts/ezs577. Epub 2012 Nov 14. No abstract available.

PMID: 3152435